Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2024 | Barriers that remain in the treatment of pediatric ALL with CAR-T therapies

Christina Peters • 15 Apr 2024
EBMT 2024
Acute Lymphoblastic Leukemia Leukemia CAR-T

Christina Peters, MD, St. Anna Children’s Hospital, Vienna, Austria, addresses ongoing challenges in CAR-T therapy for pediatric acute lymphoblastic leukemia (ALL). CAR-T is approved only for relapsed/refractory (R/R) cases, where T-cells are frequently exhausted from prior treatments like chemotherapy or allogeneic stem cell transplantation (alloSCT). Furthermore, post-CAR-T relapses often necessitate subsequent alloSCT. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Christina Peters

TBI prior to alloSCT in patients with ALL: the FORUM trials
1:57
TBI prior to alloSCT in patients with ALL: the FORUM trials
Christina Peters • 15 Apr 2024
Optimizing bridging therapy for CAR-T in children and young adults with R/R ALL
2:14
Optimizing bridging therapy for CAR-T in children and young adults with R/R ALL
Christina Peters • 15 Apr 2024
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
FORUM results: TBI vs myeloablative chemo-based conditioning pre-alloSCT in high-risk pediatric ALL
3:05
FORUM results: TBI vs myeloablative chemo-based conditioning pre-alloSCT in high-risk pediatric ALL
Christina Peters • 23 Apr 2023

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals